These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7209396)

  • 1. Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease.
    Luoma PV; Sotaniemi EA; Ehnholm C
    Scand J Gastroenterol; 1980; 15(7):869-73. PubMed ID: 7209396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
    Luoma PV; Sotaniemi EA; Pelkonen RO; Arranto A; Ehnholm C
    Eur J Clin Pharmacol; 1982; 23(3):275-82. PubMed ID: 7173298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impairment of drug metabolism in polycystic non-parasitic liver disease.
    Sotaniemi EA; Luoma PV; Järvensivu PM; Sotaniemi KA
    Br J Clin Pharmacol; 1979 Oct; 8(4):331-5. PubMed ID: 508507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between plasma high density lipoprotein cholesterol and antipyrine metabolism in alcoholics.
    Cushman P; Barboriak JJ; Liao A; Hoffman NE
    Life Sci; 1982 May; 30(20):1721-4. PubMed ID: 7098769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics.
    Luoma PV; Sotaniemi EA; Arranto AJ
    Scand J Clin Lab Invest; 1983 Dec; 43(8):671-5. PubMed ID: 6665516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma high-density lipoproteins and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction.
    Luoma PV; Savolainen MJ; Sotaniemi EA; Pelkonen RO; Arranto AJ; Ehnholm C
    Acta Med Scand; 1983; 214(2):103-9. PubMed ID: 6624542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.
    Farrell GC; Cooksley WG; Powell LW
    Eur J Clin Pharmacol; 1979 Sep; 16(2):113-7. PubMed ID: 499307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased catabolism of high density lipoprotein in alcoholic hepatitis.
    Nestel PJ; Tada N; Fidge NH
    Metabolism; 1980 Feb; 29(2):101-4. PubMed ID: 7354719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects.
    Luoma PV; Rautio A; Stengård J; Sotaniemi EA; Marniemi J
    Eur J Clin Pharmacol; 1990; 38(6):625-7. PubMed ID: 2373138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atherosclerosis of retinal arteries in men: role of serum lipoproteins and apoproteins.
    Tedeschi-Reiner E; Reiner Z; Sonicki Z
    Croat Med J; 2004 Jun; 45(3):333-7. PubMed ID: 15185429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel.
    Pazzucconi F; Malavasi B; Galli G; Franceschini G; Calabresi L; Sirtori CR
    Clin Pharmacol Ther; 1991 Mar; 49(3):278-84. PubMed ID: 1826096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equilibrium of apoproteins between high density lipoprotein and the aqueous phase: modelling of in vivo metabolism.
    Ponsin G; Pownall HJ
    J Theor Biol; 1985 Jan; 112(1):183-92. PubMed ID: 3974262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver histological changes and plasma high density lipoproteins in man.
    Luoma PV; Arranto AJ; Ehnholm C; Sotaniemi EA
    Res Commun Chem Pathol Pharmacol; 1981 Jul; 33(1):163-74. PubMed ID: 7268203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.
    Joven J; Villabona C; Vilella E; Masana L; Albertí R; Vallés M
    N Engl J Med; 1990 Aug; 323(9):579-84. PubMed ID: 2381443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid and apoprotein levels in myocardial infarction survivors. A case-control study.
    Deslypere JP; De Backer G; Rosseneu M; Vermeulen A
    Acta Cardiol Suppl; 1981; 27():95-102. PubMed ID: 6977978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipyrine kinetics in liver disease and liver transplantation.
    Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
    Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of procetofen on serum lipids and apoproteins.
    Capurso A; Mogavero AM; Taverniti R; Resta F; Pace L; Bonomo L
    Int J Clin Pharmacol Ther Toxicol; 1984 Apr; 22(4):194-7. PubMed ID: 6715088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease.
    Forrest JA; Finlayson ND; Adjepon-Yamoah KK; Prescott LF
    Br Med J; 1977 May; 1(6073):1384-7. PubMed ID: 861646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
    Branch RA; James JA; Read AE
    Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.